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Background: An effective AIDS vaccine remains one of the highest priorities in HIV-research. Our recent study
showed that vaccination of rhesus macaques with recombinant simian varicella virus (rSVV) vector – simian
immunodeficiency virus (SIV) envelope and gag genes, induced neutralizing antibodies and cellular immune
responses to SIV and also significantly reduced plasma viral loads following intravenous pathogenic challenge with
SIVMAC251/CX1.
Findings: The purpose of this study was to define cellular immunological correlates of protection in rSVV-SIV
vaccinated and SIV challenged animals. Immunofluorescent staining and multifunctional assessment of SIV-specific
T-cell responses were evaluated in both Experimental and Control vaccinated animal groups. Significant increases in
the proliferating CD4+ T-cell population and polyfunctional T-cell responses were observed in all
Experimental-vaccinated animals compared with the Control-vaccinated animals.
Conclusions: Increased CD4+ T-cell proliferation was significantly and inversely correlated with plasma viral load.
Increased SIV-specific polyfunctional cytokine responses and increased proliferation of CD4+ T-cell may be crucial to
control plasma viral loads in vaccinated and SIVMAC251/CX1 challenged macaques.
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VaccineFindings
An effective human immunodeficiency virus type 1
(HIV-1) vaccine is needed to control the HIV pandemic.
The use of live attenuated viruses as vaccines has
demonstrated protection from rigorous homologous and
heterologous viral challenges in macaques, thus provid-
ing critical proof-of-concept for the feasibility of the de-
velopment of an effective HIV vaccine to prevent or* Correspondence: vtraina@tulane.edu
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reproduction in any medium, provided the orlimit HIV infection [1-3]. The result of clinical trial in
Thailand testing with various subtype B canarypox-HIV-
1 recombinant vaccine candidates and boosters contain-
ing subunit glycoprotein 120 or 160 did not generate
strong cellular or detectable neutralizing antibody
responses to HIV-1 yet showed marginally significant
protection from infection [4]. A recent study with
adenovirus/poxvirus and adenovirus/adenovirus-vector-
based simian immunodeficiency virus (SIV) vaccine was
shown to block acquisition of pathogenic heterologous,
neutralization-resistant challenge virus in the rhesus ma-
caque (RM) model [5]. A similar study with persistent
cytomegalovirus (CMV) vector-based SIV vaccine wastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.virologyj.com/content/9/1/160able to control highly pathogenic SIV infection by indu-
cing effector memory T-cell responses [6]. So far, the de-
velopment of an effective HIV vaccine that is capable of
protecting new infection remains elusive.
Live-attenuated varicella-zoster virus (VZV) Oka





















































































































Figure 1 Percentages of (A) naïve (CD28+CD95-), (B) central memory
T-cells in peripheral blood of both Experimental (EG) and Control gro
progressive increase in both groups following immunization. A significant i
group compared to EG after SIV challenge. Following challenge there was
T-cell population respectively in both EG and CGs of animals. Cells were ga
were collected by gating on lymphocytes. Percentages of respective cell p
post vaccination and post challenge time points, in days, respectively. Black
significant difference between EG (n= 5) and CG (n = 4) for the specified ceimmunization against VZV infection (chickenpox and
shingles). This strongly immunogenic herpes virus vac-
cine backbone provides an attractive candidate for
designing recombinant vaccines [7]. Periodic subclinical
reactivation of VZV from latency may provide persistent












(CD28+CD95+) and (C) effector memory (CD28-CD95+) CD3+
up (CG) of macaques. Note that naïve T-cell population showed
ncrease in naïve T-cell population was observed in animals from CG
increased and decreased expansion of effector and central memory
ted through CD3+ “bright” T lymphocytes and at least 20,000 events
opulation represent cells out of total lymphocytes. PV and PC denote
arrow shows the time of SIVMAC251 challenge. Asterisk (*) indicates a
ll subset using the Student’s t-test, with a significance level of p < 0.05.
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http://www.virologyj.com/content/9/1/160Due to stringent VZV host-range restrictions, the simian
counterpart virus, simian varicella virus (SVV), with estab-
lished RM models of both varicella and AIDS, provide an
alternative experimental approach to investigate varicella
pathogenesis and AIDS vaccine development [8,9]. Our
recent study using recombinant SVV (rSVV) expressing
SIV Gag+Env antigens (rSVV-SIVMAC239Gag and rSVV-
SIV MAC239Env) demonstrated reduced plasma viral loads
(VLs) in five immunized RMs (Experimental Group, EG)
following intravenous SIVMAC251/CX1 challenge, when
compared to four Controls vaccinated (rSVV-RSVG
and SVV-RSVM2) RMs (Control Group, CG) challenged
with SIVMAC251/CX1 [10]. These results highlight the
strengths and success of the SVV model to evaluate SIV/
HIV vaccine candidates [10,11].
The present study investigates the role of cellular im-
mune responses in rSVV-SIV immunized animals to
define correlates of protection. All animals (EG and CG)
were negative for HIV-2, SIV, type D retrovirus and





























































Figure 2 Peripheral blood mononuclear cell proliferation assessed by
cells. Both CD4+ and CD8+ T-cell proliferation increased following SIVMAC2
Experimental group (EG) maintained higher proliferation rates compared to
and CGs returned to baseline thereafter. Cells were gated through CD3+ “b
gating on lymphocytes. Asterisk (*) indicates significant differences betwee
Student’s t-test, with a significance level of p < 0.05.animals were housed at the Tulane National Primate
Research Center (TNPRC) and under the full care of
TNPRC veterinarians in accordance with the standards
incorporated in the Guide to the Care and Use of
Laboratory Animals (NIH) 78–23 (Revised, 1996). All
veterinary procedures were performed only with sedated
animals. All animal procedures were reviewed and
approved by the Tulane Institutional Animal Care and
Use Committee. The levels of T-cell proliferation, memory
cell populations, polyfunctional T-cell responses in PBMC
were assessed by flow cytometry and their responses were
correlated with plasma VLs. In brief, T-cell immunophe-
notyping and Ki67 staining were performed using anti-
CD3-FITC/PerCP (SP34-2), CD4-APC (L200), CD8-PE/
PerCP (RPA-T8), CD95-FITC (DX2), CD28-PE (CD28.2)
and anti-Ki67-PE (B56) monoclonal antibodies (mAbs)
obtained from BD Biosciences (BD) as reported earlier
[12]. Data was acquired on a FACS Calibur flow cytometer
using BD CellQuest software and analyzed using FlowJo












 T cells 
+ T cells 
%Ki67 expression is shown in CD3+CD4+ (A) and CD3+CD8+ (B)
51 infection between 14 and 42 days of infection, but CD4+ T-cells in
Control group (CG). In contrast, proliferation in CD8+ T-cells both EGs
right” T lymphocytes and at least 20,000 events were collected by
n EG (n = 5) and CG (n = 4) for the specified cell subsets using the


























Figure 3 An inverse correlation is shown between the CD3
+CD4+ T-cell proliferation responses and plasma viral load in
Experimental group (red squares, n = 5) and Control groups
(blue circles, n = 4) of macaques following SIVMAC251 challenge
for all timepoints from d14 and d231. Note that the lower viral
loads demonstrated in the EG showed higher % of CD4+Ki67+ T-cells
while the CG that had much higher viral loads had a lower % of CD4
+Ki67+ T-cells. Interestingly, the one exception in EG overall trend was
the high viral load at the d14 peak, yet the correlation held and at that
point, the % of CD4+Ki67+ T-cells was low. Linear regression analysis
of proliferating CD4+ T-cells and mean plasma viral load from all
macaques was calculated using GraphPad Prism (version 5.0d,
GraphPad software, CA).
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http://www.virologyj.com/content/9/1/160The naïve (CD28+CD95-) T-cell population increased
in both groups following rSVV immunization (Figure 1A),
and is possibly due to heightened immune functioning,
although neither increase was statistically significant. Fol-
lowing SIV challenge, however, the CG animals continued
with a sharp rise from 28.4% on day of challenge (doc) to
35.2% on d14 post-challenge (d14pc) and remained high
for the d231pc monitoring period (23%-37%). These find-
ings were significantly different (p < 0.05) and in contrast
to the homologous SIV challenged EG animals, with 20%
naïve T-cells on doc and continued progressive de-
cline to 8% at d231pc. This decline is likely due to a
higher recruitment of naïve cells to SIV specific memory
cells in this EG. Conversely, the central memory (CD28+
CD95+) T-cell population was maintained in both groups
following immunization. After SIV challenge, a selective
depletion of central memory T-cells was observed in both
CG [22.9% (doc), 15.3% (d14pc), 10% (d119pc)] and EG
[22% (d14pc), 15% (d119pc)] with no statistically signifi-
cant differences within groups (Figure 1B). Finally, the
effector memory (CD28-CD95+) T-cells peaked on d14pc
with mean values 22.5% and 28.0%, in CGs and EGs
respectively. This cell population decreased in both groups
over the next two months to 15% followed by a gradual
increase, slightly greater in the EG over the CG, although
not statistically significant (Figure 1C). This sustained
increase in the effector memory cell population following
SIV challenge is thought to be due to the loss of the cen-
tral memory T-cell population and induction of antiviral
functions in plasma viral load reduction in both EG and
CG animals.
Next, we analyzed the level of proliferation in CD3
+CD4+ T-cells and CD3+CD8+ T-cells to determine the
impact of rSVV-SIV vaccination in response to SIV chal-
lenge (Figure 2). Following SIV challenge, an initial sharp
increase in CD4+Ki67+ proliferating T-cells was ob-
served in both vaccinated groups. The EG mean levels
rose from 1.3% (doc) to 3.6% (d28pc) and maintained at
significantly higher levels (P < 0.001) for the d231pc. The
CG mean rose to 2.2% (d28pc), was transient however,
decreased to baseline levels by d84pc and maintained
lower than the EG for the remainder of the monitoring
period. Similar increases in CD4+Ki67+ cells have also
been observed in HIV-1 and pathogenic SIV infections
[13-15]. An immediate increase in CD8+Ki67+ T-cells
was observed in both EG and CG that was short-lived
and returned to baseline by d28pc, supporting the simi-
lar expansion of CD8+ cells in peptide vaccine and SIV
pathogenesis studies reported elsewhere [12,14].
Mean levels of plasma viremia were correlated with
percentages of proliferating (Ki67+) CD4+ and CD8+ T-
cells for both EG and CGs at each of the time points
post SIV challenge (d14pc to d231pc). Pearson coeffi-
cient of determination analysis of these independentmeasures showed a highly significant inverse correlation
of the proliferating CD4+Ki67+ T-cells and plasma
viremia, regardless of treatment or timepoint (Figure 3).
Linear regression analysis of these data resulted in a
straight line with a slope 0.92 ± 0.15 (r2 =−0.702;
p < 0.0001). All correlated values for the CG showed low
levels of CD4+Ki67+ T-cells (0.9–2.2%) and high plasma
VLs (log6.3–7.6 copies/ml) while all values but one for the
EG had high levels of CD4+Ki67+ T-cells (2.5–4.1%)
and low plasma viral loads (log4.7 – 5.6 copies/ml).
The initial high viremic spike (log6.8 copies/ml) in the
EG at d14pc also correlated with a low level of CD4
+Ki67+ T-cells (1.8%) (Figure 3).
To assess the magnitude and functional characteristics
of SIV specific CD4+ and CD8+ T-cells from both
groups of animals, intracellular cytokine staining was
performed with proper positive and negative controls as
described earlier [16]. Resuspended PBMCs at 14 days
post immunization (d14pi), doc and d231pc time points
were stimulated with SIV-Gag (cat. 6204) and Env
(cat. 6883) peptide pools (NIH AIDS Research & Refer-
ence Reagent Program) in the presence of 0.5ug/ml of
anti-CD28 (clone CD28.2, BD) and anti-CD49d (clone
9F10, BD) mAbs. Following stimulation, the cells were
stained for live/dead stain (Invitrogen), then surface stain-
ing with anti-CD3, anti-CD4, anti-CD8; and intracellular
staining with anti-IL2 (MQ1-17H12), anti-IFNγ (4S.B3),
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http://www.virologyj.com/content/9/1/160and anti-TNFα (MAb11) mAbs. Data acquisition was per-
formed on fixed stained cells using BD LSRII flow cyt-
ometer and analyzed using FlowJo software, version 9.1.
[16] (Additional file 1: Figure S1). The analysis andFigure 4 Intracellular cytokine responses measured against SIV-Env (A
were shown. PBMC were unstimulated (medium control) or stimulated for
immunization, day of challenge and 231d post challenge time points. Cells
on CD3+ T-cells and subsequently on CD3+CD4+ and CD3+CD8+ T-cell su
presence of IFNγ, TNFα and /or IL2 positive cells by using Flowjo, and SPIC
CD4 and CD8 T-cells, however the antigen specific CD4 responses were hig
were also higher compared to SIV-Env antigens. Individual animal response
respective responses from all animals (n = 5). Positive symbols represent ce
represent cells staining negative for a cytokine response. The presence of t
producing cells and single cytokine producing cells are denoted under the
and 1 cytokine(s) respectively. The criterion for a positive cytokine response
cytokine above the medium control culture. All values were subtracted frompresentation of cytokine expression was performed for
each animal after proper antigenic stimulation and using
SPICE software version 5.2, downloaded from http://exon.
niaid.nih.gov/spice (Figure 4). In brief, cytokine responses) and SIV-Gag (B) antigens in Experimental vaccinated macaques
6 h with different SIV-Env and/or SIV-Gag peptide pools at 14d post
were gated on singlets, lymphocytes, followed by live cells and then
bsets. CD3+CD4+ or CD3+CD8+ T-cells were further analyzed for the
E software. Increased polyfunctional responses were detected both in
her compared to CD8 specific responses. SIV-Gag specific responses
s are depicted by each dot and gray bars represent mean values of
lls staining positive for a cytokine response, and minus symbols
hree different cytokine producing cells, two different cytokine
bottom-most graphs (left to right) for each CD4 and CD8 cells as 3, 2
was a two-fold increase in frequency for that specific antigen and
medium control before the analysis.
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http://www.virologyj.com/content/9/1/160produced by macaques are either monofunctional (mono,
producing any one cytokine), bifunctional (bi, any com-
bination of two different cytokines), or trifunctional (tri,
producing three cytokines) cells and are diagrammatically
represented in Figure 4. Recombinant SVV Experimentally
immunized macaques (EG) generated SIV-Env specific
monoCD4+, (mean values 0.50%, 0.66%, 0.12% on d14pi,
doc, d231pc respectively) as well as biCD4+ (0.01%,
0.01%, 0.03% on d14pi, doc, d231pc respectively) (Figure 4,
Additional file 2: Figure S2, Table 1). SIV-Env specific
CD8+ responses were also demonstrated in the rSVV vac-
cinated EG macaques with monoCD8+ mean value
responses of 0.08%, 0.18%, 0.02%; and biCD8+ mean
values of 0.01%, 0.03%, 0.0% at d14pi, doc, d231pc respect-
ively. In contrast, Control vaccinated (CG) macaques pro-
duced responses for SIV-Env specific cells with results of
monoCD4 mean values of 0.0%, 0.0%, 0.19%; biCD4 mean
values 0.0%, 0.0%, 0.0%; monoCD8 mean values 0.0%, 0.0%,
0.05%; and biCD8 mean values 0.0%, 0.0%, 0.0% on d14pi,
doc, d231pc respectively (Figure 4, Additional file 2:
Figure S2, Table 1). These data show that all EG macaques
demonstrated substantial SIV specific cytokine responses in
both CD4 and CD8 cells at pre challenge time points with
CD4 responses greater than CD8 cytokine responses. All
CG macaques were completely negative for SIV specific
CD4+ and CD8+ cytokine responses at those prechallenge
time points (Table 1). Postchallenge results showed positive
cytokine expression in 4 out of 5 EG animals and 2 out of 4
CG animals (Additional file 2: Figure S2). Mean responses
were lower in both groups (EG and CG), compared to the
prechallenge responses, possibly due to immunosuppres-
sion in this late chronic phase of the SIV infection
(Table 1).
Although we tested only one timepoint (d14pi) for
SIV-Gag specific responses in EG, the values were 1.5-10
times higher than the SIV-Env specific responses at thisTable 1 Frequency of SIV antigen-specific cytokine producing
Animal group SIV Antigen Mono* d14pi do
Experimental (EG) Env CD4 0.50% 0.
Env CD8 0.08% 0.
Gag CD4 0.86% ND
Gag CD8 0.43% ND
Control (CG) Env CD4 0.00% 0.0
Env CD8 0.00% 0.0
Gag CD4 0.06% 0.0
Gag CD8 0.05% 0.0
(^) - Percentages are calculated means for each animal group.
Mono* - Monofunctional cytokine producing cells.
Bi** - Bifunctional cytokine producing cells.
ND – Not determined.
d14pi – d14 post-inoculation.
doc – day of challenge.
d231pc – d231 post-challenge.d14pi time point. EG animals showed SIV-Gag specific
monoCD4+ response mean of 0.86%, monoCD8+ mean of
0.43%, biCD4+ mean 0.79% and biCD8+ mean 0.18%, were
higher when compared with CG responses for monoCD4+
mean 0.06%, biCD4+ mean 0.05%, monoCD8+ mean
0.05%, and biCD8+ mean 0.01% at d14pi. CG animals only
were additionally tested for Gag-specific cytokine responses
on doc and d231pc with no detectable responses for any
animal in this group (Table 1). These findings demonstrate
greater mono and polyfunctional responses during prechal-
lenge time points in the EG over the CG animals and that
CD4+ T-cells play a major role in inducing increased cyto-
kine responses compared to CD8+ T-cells. In addition, al-
though only at the one time-point tested, the gag-specific
responses were greater than the Env-specific responses in
EG animals compared to CG animals.
The increased CD4+ T-cell proliferation and profound
SIV-Gag and Env specific cytokine responses in Experi-
mental vaccinated macaques suggest that those prolifer-
ating CD4+ T-cells may be effector cells and their SIV-
specific effector functions contributed significantly to
control plasma VLs. Low to minimal neutralizing anti-
body responses in those rSVV-SIV vaccinated animals
[10] also suggest that SIV-specific cytokine responses
may play a crucial role in controlling plasma VLs and
disease progression. Vaccine induced increased CD4+
T-cell proliferation and cytokine responses support earlier
observations where HIV-specific CD4 T-cells were thought
to be responsible for enhanced immunological control of
HIV viremia either by helping CD8 T and B cells [17] or by
direct antiviral effects [18,19]. Enhanced HIV-specific
CD4 T-cells cytokine responses were also demonstrated
in individuals that are able to control viral replication
spontaneously in the absence of antiretroviral therapy
[20,21]. Finally, with only a small percentage of HIV-
specific CD4+ T-cells preferentially infected by HIV, thecells in vaccinated animals^
c d231pc Bi ** d14pi doc d231pc
66% 0.12% CD4 0.10% 0.01% 0.03%
18% 0.02% CD8 0.01% 0.03% 0.00%
ND CD4 0.79% ND ND
ND CD8 0.18% ND ND
0% 0.19% CD4 0.00% 0.00% 0.00%
0% 0.05% CD8 0.00% 0.00% 0.00%
0% 0.00% CD4 0.05% 0.00% 0.00%
0% 0.00% CD8 0.01% 0.00% 0.00%
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and capable of inducing antiviral activity [22].
In conclusion, it is still unclear what constitutes the cor-
relates of protection and what early immune responses are
required to prevent early virus dissemination, viral replica-
tion, and viral transmission. In an effort to define those
correlates, this vaccine study shows that increased CD4+
T-cell proliferation and increased SIV-antigen specific
mono and polyfunctional CD4 and CD8 responses in the
rSVV-SIVEnv/Gag vaccinated animals are key correlates of
vaccine-mediated protection. These results show signifi-
cant promise for rSVV-SIV vaccines as an effective pre-
clinical approach to test potential recombinant AIDS
vaccines with subsequent translation into rVZV-HIV vac-
cination in humans.
Additional files
Additional file 1: Figure S1. Intracellular cytokine flow cytometry for
IFNγ, TNFα and IL2 responses from a representative rSVV-SIVEnv and
rSVV-SIVGag vaccinated rhesus macaque. Cells were gated first on
singlets, lymphocytes, followed by live cells and then on CD3+ T-cells
and subsequently on CD3+CD4+ and CD3+CD8+ T-cell subsets. The
percentages of IFNγ, TNFα and /or IL-2 positive cells are shown in each
upper box of each plot. Note that this vaccinated animal has an
increased SIV-Gag specific IFNγ response.
Additional file 2: Figure S2. Intracellular cytokine responses measured
against SIV-Env and SIV-Gag antigens in Control vaccinated macaques
were shown. PBMC were unstimulated (medium control) or stimulated
for 6 h with different SIV-Env and/or SIV-Gag peptide pools at 14d post
immunization (d14pi), day of challenge (doc) (A & B) and 231d post
challenge (pc) time points (C & D). Cells were gated and analyzed as
mentioned in Figure 4. All the animals had low to negative SIV antigen-
specific responses detected at d14pi and doc of vaccination time points
(A & B). Monofunctional responses were detected either in CD4 or CD8
T-cells from 2 out of 4 macaques and were limited to TNFα responses,
however the antigen specific CD4 responses were higher compared to
CD8 specific responses at d231pc time point (C & D). Individual animal
responses are depicted by each dot and gray bars represent mean values
of respective responses from all animals (n = 4). Positive symbols
represent cells staining positive for a cytokine response, and minus
symbols represent cells staining negative for a cytokine response. The
presence of three different cytokine producing cells, two different
cytokine producing cells and single cytokine producing cells are denoted
under the bottom-most graphs (left to right) for each CD4 and CD8 cells
as 3, 2 and 1 cytokine(s) respectively. The criterion for a positive cytokine
response was a two-fold increase in frequency for that specific antigen
and cytokine above the medium control culture. All values were
subtracted from medium control before the analysis.
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